Energy Tech Nexus has opened in downtown Houston. Photo by Natalie Harms/EnergyCapital

Three Houston energy innovators have cut the ribbon on a new space for energy transition innovation.

The Energy Tech Nexus, located in the historic Niels Esperson Building at the corner of Travis and Rusk Avenue, opened on September 10, which was proclaimed Energy Tech Nexus Day by the city.

Jason Ethier and Juliana Garaizar, formerly in leadership roles at Greentown Labs, teamed up with Nada Ahmed, previously headed innovation and transformation at Aker Solutions, launched ETN as a community for energy transition startups. The new hub plans to host incubation programs, provide mentorship, and open doors to funding and strategic partnerships for its members.

"We are creating more than a space for innovation," Garaizar, who serves as CEO of ETN, says in a news release. "We are crafting a community where pioneers in technology and energy converge to challenge the status quo and accelerate the shift to sustainable energy solutions."

The hub describes its goal of tackling the "trilemma" of energy security, sustainability, and affordability while also contributing to the mission of setting up Houston as the global center for energy transition. To accomplish that mission, ETN will help facilitate rapid deployment of cutting-edge energy technologies.

'The future of energy is not just being written here in Houston; it's being rewritten in more sustainable, efficient, and innovative ways," adds Garaizar. "Houston provides the perfect backdrop for this transformation, offering a rich history in energy and a forward-looking approach to its challenges and opportunities."

"We believe that a broad spectrum of perspectives is crucial in solving global energy challenges. It's about bringing everyone to the table — startups, industry leaders, and investors from all backgrounds," she continues.

Ethier, who co-hosts the Energy Tech Startups Podcast with Ahmed, says he hopes that ETN acts as a meeting place for energy transition innovators.

"By providing the right tools, access, and expertise, we are enabling these companies to leap from ideation to implementation at an unprecedented pace;" Ethier explains. "The interaction between startups and established companies within Energy Tech Nexus creates a unique synergy, fostering innovations that might otherwise take years to mature in isolation."

Payal Patel, an angel investor who has held leadership roles at Station Houston, Plug and Play Ventures, and Softeq, also contributed to launching ETN, which is collaborating with George Liu, who has over 15 years of investment banking experience across energy, cleantech and hardtech with more than $20 billion in M&A projects across his career.

In May, ETN teamed up with Impact Hub Houston to establish the Equitable Energy Transition Alliance and Lab to accelerate startup pilots for underserved communities. The initiative announced that it's won the 2024 U.S. Small Business Administration Growth Accelerator Fund Competition, or GAFC, Stage One award.

ETN celebrated its opening during the inaugural Houston Energy and Climate Week.

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”